Cargando…

The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan

BACKGROUND: There is no consensus on the appropriate surveillance for high-risk women with breast cancer in Japan. We investigated their imaging features and pathological characteristics to build a proper surveillance system for asymptomatic high-risk individuals in the future. METHODS: We retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murakami, Wakana, Tozaki, Mitsuhiro, Nakamura, Seigo, Ide, Yoshimi, Inuzuka, Mayuko, Hirota, Yuko, Murakami, Kouzou, Takahama, Noritsugu, Ohgiya, Yoshimitsu, Gokan, Takehiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694035/ https://www.ncbi.nlm.nih.gov/pubmed/30820924 http://dx.doi.org/10.1007/s12282-019-00955-6

Ejemplares similares

BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ
por: Liu, Yan, et al.
Publicado: (2019)

Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan
por: Tozaki, Mitsuhiro, et al.
Publicado: (2017)

Intracardiac Thrombosis and Heart Failure in a Patient with Hepatocellular Carcinoma and Cardiac Amyloidosis and an Implanted Cardiac Resynchronization Therapy Device
por: Akutsu, Yasushi, et al.
Publicado: (2019)

Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X
por: Yoshida, Reiko, et al.
Publicado: (2019)

Accumulation of (123)I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson’s Disease
por: Murakami, Hidetomo, et al.
Publicado: (2017)

Development of an artificial intelligence-assisted computed tomography diagnosis technology for rib fracture and evaluation of its clinical usefulness
por: Niiya, Akifumi, et al.
Publicado: (2022)

MR Imaging of Fetuses to Evaluate Placental Insufficiency
por: OHGIYA, Yoshimitsu, et al.
Publicado: (2015)

Impact of Japan’s State of Emergency Due to the COVID-19 Pandemic on Trends in Diabetes Care: A Descriptive and Retrospective Study
por: Minoura, Akira, et al.
Publicado: (2023)

Impact of the state of emergency on trends in the care of three major diseases at Showa University Hospital, Japan: a retrospective and descriptive study
por: MINOURA, AKIRA, et al.
Publicado: (2022)

Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2‐mutation carriers
por: Mori, Tomoharu, et al.
Publicado: (2022)

Prevalence of disease-causing genes in Japanese patients with BRCA1/2-wildtype hereditary breast and ovarian cancer syndrome
por: Kaneyasu, Tomoko, et al.
Publicado: (2020)

The intrinsic ability of double-stranded DNA to carry out D-loop and R-loop formation
por: Shibata, Takehiko, et al.
Publicado: (2020)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
por: Yamauchi, Hideko, et al.
Publicado: (2023)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

Prostate screening uptake in Australian BRCA1 and BRCA2 carriers
por: McKinley, Joanne M, et al.
Publicado: (2007)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Gastric Cancer Risk and Pathogenesis in BRCA1 and BRCA2 Carriers
por: Buckley, Kole H., et al.
Publicado: (2022)

Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
por: Yamauchi, Hideko, et al.
Publicado: (2023)

Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
por: Nomura, Hidetaka, et al.
Publicado: (2023)

Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants
por: Momozawa, Yukihide, et al.
Publicado: (2022)

Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
por: Sekine, Masayuki, et al.
Publicado: (2022)

BRCAness as a prognostic indicator in patients with early breast cancer
por: Liu, Lei, et al.
Publicado: (2020)

Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
por: Tai, Yu Chuan, et al.
Publicado: (2008)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2017)

Correction: Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan
por: Arai, Masami, et al.
Publicado: (2018)

Managing BRCA Mutation Carriers in China: Reply
por: Kwong, Ava, et al.
Publicado: (2010)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers
por: Paolino, Giovanni, et al.
Publicado: (2022)

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay
por: Baert, Annelot, et al.
Publicado: (2017)

Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells
por: Hakiri, Shuhei, et al.
Publicado: (2015)

Central Nervous System Effects of the Second-Generation Antihistamines Marketed in Japan -Review of Inter-Drug Differences Using the Proportional Impairment Ratio (PIR)-
por: Isomura, Tatsuya, et al.
Publicado: (2014)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_mgu78kpa1lg2ku280o41qevjuf